Introduction
Scleroderma or systemic sclerosis (SSc) is a progressive autoimmune connective tissue disease associated with progressive fibrosis of skin and numerous internal organs. 1 The gastrointestinal (GI) tract is the most common internal organ system affected in SSc with as many as 90% of the patients developing esophageal symptoms. 2, 3 Interestingly, a large percentage of SSc patients display involvement of the anorectum, causing alterations of the IAS function and frequent fecal incontinence. [4] [5] [6] GI dysmotility in SSc is believed to be neuropathic in origin, with subsequent smooth muscle atrophy and fibrosis. 2 The early stages may involve neuropathic changes in the cholinergic innervation, and in the latter stages there are myopathic changes. 2, 7 Following earlier studies by Bacman and colleagues on the presence of circulating M 3 -R in patients with Sjögren's syndrome, 8 Goldblatt et al. 9 demonstrated the presence of such antibodies in SSc patients. These antibodies caused significant dysfunction in the mouse colonic smooth muscle contraction induced by the M 3 -R agonist, carbachol.
These studies suggested that neuropathic gastrointestinal dysfunction caused by circulating antibody interference with cholinergic innervation was responsible for GI dysmotility in SSc. Our recent studies using isolated SMCs of the rat IAS demonstrated that SScIgGs cause ~50% inhibition of M 3 -R activation and suggested that this mechanism in part is responsible for the GI smooth muscle myopathy in SSc. 10 None of the above studies, however, neither examined the status of the actual cholinergic innervation and its effects in human SMCs, nor investigated the possible reversal of SScIgGs' effects.
Because of the lack of clear understanding of the SSc pathophysiological mechanism/s, there is no effective disease modifying treatment for SSc. Pooled human IgG (pooledhIgG) also known as intravenous immunoglobulin (IVIG) has been clinically employed as a potent immunomodulating agent in various immune-mediated disorders. [11] [12] [13] The use of pooledhIgG for the treatment of SSc has been supported by studies in the tight skin (TSK) animal model of SSc demonstrating that pooledhIgG may cause beneficial effects 14 either by counteracting antifibroblast antibodies or decreasing expression of the type I collagen gene, 15 as well as by modulating the secretion of profibrotic cytokines TGFβ1 and IL-4. 14, 16 However, the exact mechanisms of action of pooledhIgG in SSc are not known. Thus, owing to the potential pathogenetic role of circulating antibodies in SSc-related GI dysmotility it will be important to determine the effect of pooledhIgG in SSc in inhibition of the effect of SScIgGs against M 3 -R.
In the present study we determined the site of action of the M 3 -R autoantibodies present in SScIgGs using rat colon to assess a cholinergic involvement, and then assessed the myopathic changes using human IAS SMC and rat IAS smooth muscles. The studies also investigated the role of pooledhIgG in reversing the cholinergic blockade by SScIgGs in these systems. 
Materials and Methods

Isolation and Purification of IgGs from SSc Patients and Normal Volunteers
Human IAS Tissue Samples and SMCs Isolation
Human IAS smooth muscle tissue samples were obtained from five subjects who underwent surgical removal of the anorectal region. SMCs from the circular smooth muscle layer of the IAS were isolated as described previously. 10 Isolated cells were resuspended in DMEM growth medium with 5% fetal bovine serum and antibiotics on Lab-Tek II chamber slides (Nulgene Nunc International, Naperville, IL) at 37°C and 5% CO 2 in an incubator with regulated humidity.
Experiments in Human SMCs
Effect of SScIgGs, NIgGs and PooledhIgG on Human IAS SMC Contraction
The SMCs isolated as described above were divided into different aliquots, and their responses to bethanechol (BeCh; 10 -9 to 10 -4 M) before and after SScIgG, NIgG , pooledhIgG (0.1 to 1 mg/ml) and the combination of either pooledhIgG and SScIgG or pooledhIgG and NIgG (0.1 to 1 mg/ml each) for 10 min, were determined. In some experiments, we also examined the effects of higher concentrations (10 mg/ml) of pooledhIgG. The cells were then fixed with acrolein (final concentration 1%) and cell length was measured by using digital micrometry. 10 To determine the selectivity of action of the SScIgG on the M 3 -R activation by BeCh, we compared the effects of different IgGs and their combinations on α 1 -adrenoceptor (α 1 -AR) activation by phenylephrine (10 -9 to 10 -4 M), and K + -depolarization with KCl (2.5 mM to 40 mM).
Immunofluorescence Analysis
The human IAS SMCs were quickly rinsed with Dulbecco's phosphate-buffered saline (DPBS) and non specific antibody binding sites were blocked with 1% FBS in DPBS. To determine the membrane binding efficiency of SScIgG, vs NIgG and pooledhIgG, SMCs were incubated with 5 µg/ml of these antibodies for different time points (0 to 30 min) at 37 0 C, and fixed with acetone for 10 min at −20°C. The cells were then washed three times with DPBS and stained with the anti-human IgG-FITC-conjugated antibody as described previously. 20 Cells were co-stained with 5µg/ml of anti-M 3 -R antibody, as an internal control to detect colocalization of M 3 -R with SScIgG in human IAS SMCs. These cells were rinsed with DPBS and stained with anti rabbit-TR-conjugated antibody. The cells were finally stained with nuclear staining dye DAPI and images were taken employing a Nikon Eclipse 80i microscope as described previously. 20
Immunofluorescence Intensity (IFI) Calculation
IFI was calculated by using NIS Elements 3.1 software by two different methods as follow: a). Intensity per unit area: For this purpose, 20 µm 2 of cell membrane area was selected at four different sites of the cell membrane and pixel intensity under this area was calculated and plotted as a bar graph ( Fig. 2B and E). The above procedure was repeated in 20 randomly selected cells and calculated as means ± SE. b). Line graph method: For this purpose, intensity under a line of 1-µm width across the cell avoiding the nucleus was calculated and plotted for the membrane IFI of different IgGs (Fig. 3A) . The Pearson's colocalization coefficient was determined for each cell and Mean ± SE was calculated and plotted ( Fig. 3B ). 21
Western Blot (WB) Analyses for Interaction of SScIgGs vs. NIgGs and pooledhIgG with M 3 -R
These studies were performed to determine the binding of SScIgG vs. NIgG, and pooledhIgG to M 3 -R in human IAS SMC membrane fractions (HISMF) prepared following a previously described method. 22 The membrane protein was electrophoresed on 7.5% SDS-PAGE and transferred to a PVDF membrane by using iBlot. 7 The membrane was subdivided into five equal parts that were kept in blocking buffer (5% bovine serum albumin in Tris buffer saline pH 7.2) for 1 h. These membranes were separately incubated overnight at 4°C with 5 µg/ml of M 3 -R antibody, SScIgG, NIgG, pooledhIgG, and pooledhIgG+SScIgG, washed three times with TBS containing 0.1% Tween (TBST), and stained with corresponding HRPconjugated secondary antibodies. The membranes were washed three times for 10 min with TBST, and stained with tertiary antibody against HRP (Chemi IR detection system from LI-COR biosciences) for 1 h at RT in TBST containing 0.002% SDS. The membranes were washed and scanned with a LI-COR Odyssey Imaging System infrared scanner, and relative densities of M 3 -R and human IgGs were plotted using Image-J (NIH). 10 Na + -K + ATPase (a membrane marker) antibody was used as a loading control.
Enzyme-Linked Immunosorbent Assay (ELISA)
To determine direct binding of SScIgG to the M 3 -R and its interaction with pooledhIgG in the human IAS SMCs, we performed ELISA studies employing an ELISA kit (NB-E10632
from Novatein Biosciences, Inc., Cambridge, MA) using different concentrations of purified concentration of 400 pg/ml were separately dissolved in the carbonate buffer and adsorbed onto separate multiwell plates used for ELISA. 23 From 0 to 6 µg/ml of M 3 -R antibody, SScIgG, NIG, pooledhIgG, and pooledhIgG+SScIgG were added to these multiwell plates and incubated at 37 o C for 1 h. Plates were washed three times with DPBST and incubated for 1 h at RT with anti-rabbit-HRP-conjugated for M 3 -R antibody and anti-human-HRP-conjugated secondary antibodies for SScIgG, NIgG, pooledhIgG and pooledhIgG+SScIgG and washed three times with DPBST and 100 µl of TMB substrate was added and kept for 15 min at RT.
Following substrate addition, 100 µl of Stop solution was added to each well and absorbance was recorded at 450nm with ELISA reader.
Neutralization Studies
For this purpose 400 pg/ml M 3 -R peptide was adsorbed on multiwell plates (used for ELISA) and the effect of pooledhIgG on the maximal binding of the SScIgG (5 µg/ml) to the M 3 -R peptide was determined by ELISA. We substituted SScIgG alone with the mixture of SScIgG+pooledhIgG (mixed at 37 o C for 1h; pooledhIgG concentrations ranged from 0 to 15 µg/ml diluted in PBS). As a negative control for the pooledhIgG effects, we used inactivated pooledhIgG (by proteinase digestion followed by boiling). The OD readings obtained using the combination of pooledhIgG+SScIgG were compared with those of the maximal OD reading obtained with M 3 -R peptide and SScIgG alone. To determine the neutralization of the M 3 -R binding with the SScIgGs by pooledhIgG in the IAS SMC membrane, we followed the procedure described above except for substitution of M 3 -RL2 with 400 µg/ml of HISMF.
Experiments using Intact Rat Colon and IAS Smooth Muscles: Smooth Muscle Strips Preparation and Isometric Tension Recording
Cholinergic Nerve Stimulation Experiments
Male Sprague-Dawley rats (300-350 g) were euthanized by decapitation, and the lower portion of the colon was surgically removed and transferred to oxygenated (95% O 2 + 5% CO 2 )
Krebs physiological solution (KPS) at 37 o C. The composition of KPS (in mM) was: 118.07 NaCl, 4.69 KCl, 2.52 CaCl 2 , 1.16 MgSO 4 , 1.01 NaH 2 PO 4 , 25 NaHCO 3 , and 11.10 glucose. The colonic smooth muscle strips (~0.5x7 mm) from the circular smooth muscle layer were prepared for the recording of isometric tension using 2 ml organ baths as described previously. 24, 25 These smooth muscle strips were then transferred to 2 ml organ baths containing oxygenated KPS and allowed to equilibrate for 1-2 h. To determine the effects of cholinergic nerve stimulation, electrical field stimulation (EFS; 10 V, 0.25 to 10 Hz, 4 sec train, each pulse of 0.5 ms) was delivered using a Grass stimulator (model S88; Grass Instruments Co., Quincy, MA). The EFS responses (percent maximal increase in the basal activity) were quantified before and after tetrodotoxin (TTX; 10 -6 M), atropine (10 -7 M), darifenacin (10 -7 M), NIgG and SScIgG (1mg/ml), pooledhIgG (10 mg/ml), and pooledhIgG (10mg/ml)+SScIgG (1mg/ml).
Acetylcholine (ACh) Measurements
Rat colonic smooth muscles were prepared for the EFS as described above. 
Functional Displacement of M 3 -R Experiments using Intact IAS Smooth Muscle
We examined the responses to SScIgG, NIgG and pooledhIgG (0.1 to 1 mg/ml) on the sustained phase of IAS contraction by BeCh (10 -4 M). These effects were compared with those of M 3 -R antagonist darifenacin (10 -9 M to 5x10 -8 M). The basal tone in each smooth muscle strip of the colon and IAS was determined at the end of each experiment by the administration of EDTA (50 mM) and 0Ca 2+ . 25, 26 All experimental protocols were approved by the IACUC of 
Statistical Analysis
Data are presented as means ± SE of multiple experiments. P values less than 0.05 were considered statistically significant. The concentration-response curves were fitted by nonlinear regression using the computer software Prism (GraphPad Software, San Diego, CA).
Results
Effect of SScIgGs on Cholinergic Nerve Stimulation in the Colon: Studies in Intact Rat Colonic Smooth Muscles
EFS caused a frequency-dependent increase in the contraction of the colonic smooth muscles, that was attenuated by TTX, atropine, and darifenacin (*; p<0.05; n=6; Fig. 1A ),
suggesting that EFS causes contraction of the colonic smooth muscle via cholinergic nerve stimulation, partly through M 3 -R activation. The data further showed that SScIgGs (in contrast with pooledhIgG) caused significant suppression of the EFS-induced cholinergic contraction (*; p<0.05; n=6). The latter effect was reversed by 10mg/ml pooledhIgG to the level that was not significantly different from the control values (p>0.05; n=6).
Effect of SScIgGs on EFS-Evoked ACh Release in Intact Rat Colonic Smooth Muscles
Direct measurements of ACh from myenteric neurons revealed that EFS causes a significant increase in ACh release, which was significantly attenuated by 0Ca 2+ , TTX as well as by SScIgG (**; p<0.05; Fig. 1B; n=4) . A complete obliteration of the EFS-evoked release of ACh by 0Ca 2+ and TTX suggests definitive neurotransmitter release of ACh. The suppressant effects of SScIgGs on ACh release were reversed by pooledhIgG (*; p<0.05; n=4), whereas pooledhIgG by itself had no significant effects on basal release of ACh (p>0.05).
Effect of SScIgG vs. NIgG and PooledhIgG on BeCh-Induced Contraction of Human IAS SMCs
SScIgGs Fig. 2A,B ). Significant IFI with SScIg was observed at 5 and 10 min as 79.57 ± 5.43 and 89.47 ± 6.24%, respectively (*; p<0.05; n=6). Therefore, a 10 min time frame was selected for the subsequent experiments with SScIgG. In contrast with the SScIgG, NIgG and pooledhIgG (14 ± 1.5 and 16 ± 2.2%, respectively) had significantly less binding (*; p<0.05; Fig. 2C ,D,E).
Collectively, these data reveal that SScIgG has significantly higher binding to the IAS SMC membrane than NIgG and pooledhIgG. Immunofluorescence (IF) analysis also showed a significant (*; p<0.05; n=6) colocalization of the M 3 -R and SScIgG binding to the human SMC membranes, as determined by the secondary antibodies conjugated with TR and FITIC, respectively (*; p<0.05; n=6; Fig. 3A,B ). This colocalization was not observed with either NIgG or pooledhIgG.
Functional Displacement of M 3 -Receptor (M 3 -R) Occupancy by SScIgG in Rat IAS Smooth Muscle
These studies were 
Assessment of SScIgG, NIgG and PooledhIgG Binding to M 3 -R using Western Blot Analysis in Human IAS SMCs
Western blot analysis was used to confirm the binding of SScIgG to M 3 -R in HISMF, and 
Assessment of SScIgG, NIgG and PooledhIgG Binding to M 3 -R and Influence of PooledhIgG employing Human IAS SMC Membrane Lysate and M3-R loop-2 Peptide
M 3 -R specific ELISA studies revealed a concentration-dependent increase in the binding with the standard M 3 -R peptide and the HISMF (Fig. 6A) , with the maximal binding at 300 pg/ml and 300 µg/ml, respectively. Following this, we used multiwell plates (used for ELISA) preadsorbed with the maximal concentration (300 µg/ml) of the HISMF and performed ELISA using different concentrations of the IgGs for M 3 -R binding analysis (Fig. 6B) . The data showed that SScIgG (and not NIgG and pooledhIgG) binds to HISMF significantly in a concentration-dependent manner and the maximal OD at 5µg/ml of the lysate was 0.71 ± 0.05 
PooledhIgG Neutralizes the SScIGs in vitro: Studies using Human IAS SMC Membrane Extracts
In these experiments, we determined the maximal OD following incubation of 5 µg/ml of SScIgGs from different patients in multiwell plates (used for ELISA) preadsorbed with 400 pg/ml of M 3 -RL2 ( Fig. 7) . Pretreatment with pooledhIgG caused a significant and concentration-dependent decrease in this maximal OD; 15 µg/ml of pooledhIgG decreased the OD from 0.77 ± 0.34 to 0.41 ± 0.05 (*; p<0.05; n=6; Fig. 7A ). However, inactivated pooledhIgG failed to cause any decrease in the interaction between SScIgG and M 3 -RL2.
Interestingly, similar data were obtained when HISMF (400 mg/ml; Fig. 7B ) instead of M 3 -RL2 was used. Thus, these data show that neutralization of the SScIgG with pooledhIgG causes a decrease in the M 3 -R binding by the SScIgGs.
Discussion
These studies indicate several important points. Firstly, sera from patients with SSc contain antibodies of the IgG class that act both at the myenteric nerves and at the smooth muscle cell membrane receptors. Secondly, these antibodies reversibly block cholinergic nerve and muscle functions. Thirdly, the effects of these antibodies can be inhibited by pooledhIgG.
Finally, the studies show that one of the prominent sites of action of these antibodies is at M 3 Several possible mechanisms may explain the reversal of SScIgGs-induced M 3 -R inactivation by pooledhIgG including neutralization, 28, 29 desensitization, internalization or degradation of the IgGs. [30] [31] [32] Present studies provide further evidence that pooledhIgG reverses M 3 -R inactivation whether the cells are incubated with pooledhIgG followed by SScIgG or with the premixed SScIgGs and pooledhIgG. This is shown by IF, WB, ELISA, neutralization, and functional displacement of M 3 -R occupancy studies. Therefore we suggest that the effects of pooledhIgG occur primarily by binding with the SScIgG thus neutralizing the effects of these antibodies in the circulation. This hypothesis is further supported by the observations that pooledhIgG forms an immune complex with IgGs interacting with Fc γ receptors on dendritic cells thus reducing the severity of autoimmune diseases 12, 33 From the present data, we postulate that neutralization of these pathogenic antibodies by pooledhIgG may represent a novel approach for the treatment of SSc GI motility disorders by blocking cholinergic dysfunction induced by SScIgG. However, the exact mechanism, and the role of other pathways including possible removal of the SSc pathogenic antibodies in the therapeutic efficiency and efficacy of pooledhIgG remain to be determined. Previously reported studies on the effect of pooledhIgG in SSc patients 11 have primarily focused on cutaneous and articular manifestations. Therefore, the present studies that identify a novel therapeutic and potentially mechanistic role of pooledhIgG in the GI dysfunction of SSc may represent a major step forward for the treatment of SSc.
In summary, the present studies provide evidence for the proposed mechanism for the M 3 -Rmediated cholinergic dysfunction in SSc-related GI manifestations and its restoration by pooledhIgG. Collectively, we posit that neutralization of these pathogenic antibodies by pooledhIgG may in part relieve SSc-associated GI motility disorders by blocking cholinergic inhibition. Based on the long-term use of pooledhIgG in other autoimmune diseases, we suggest that pooledhIgG may provide a novel and safe therapy for the SSc-related GI motility disorders. 
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